Testosterone and Long Pulse Stimulation After SCI
Keywords
Abstract
Description
The long-term goal is to develop a rehabilitation strategy to mitigate the deleterious changes in muscle size and lower leg lean mass in persons with denervation following spinal cord injury (SCI). Currently, there is no available rehabilitation intervention following lower motor neuron (LMN) denervation. More than 46,000 Veterans are affected with SCI and may experience profound skeletal muscle atrophy and loss of lean mass and about 20-25% experience LMN denervation. Skeletal muscle cross-sectional area is 6 times smaller following LMN denervation compared to the innervated muscles. Denervation atrophy may be accompanied by several SCI health-related consequences.
Twelve weeks of twice weekly of surface neuromuscular electrical stimulation (NMES) resistance training (RT) can elicit more than a 35% increase in skeletal muscle size, decreased ectopic adipose tissue accumulation, increased insulin sensitivity after SCI. Moreover, the applicant's CDA-2 preliminary findings showed that 16 weeks of NMES-RT and testosterone replacement therapy (TRT) increased leg lean mass by 1.5 kg with no changes in the TRT group only. This was accompanied by an increase in the basal metabolic rate (BMR) of 218 kcal/day in the NMES-RT+TRT with no changes in the TRT group. During the course of recruitment for the study, 20% of individuals with SCI were excluded and could not benefit from exercising their lower extremity muscles, presumably because of LMN denervation.
Long pulse width stimulation (LPWS; 120-150 ms) has the potential to stimulate denervated muscles and to restore muscle size in people with SCI. The previous paradigm has focused on daily activation of the denervated muscles without applying progressive loading similar to RT. Daily training is not a clinically feasible approach in persons with SCI. Moreover, previous trials did not focus on enhancing the neuromuscular homeostasis by promoting the increase in lean mass independent of LMN denervation. Testosterone replacement therapy (TRT) has been shown to increase lean mass and basal metabolic rate in hypogonadal men with SCI. The investigators will determine if TRT+LPWS would increase skeletal muscle size, leg lean mass and improve overall metabolic health in SCI persons with LMN denervation. The investigators hypothesize that the one year TRT+LPWS protocol will upregulate protein synthesis pathways, down-regulate protein degradation pathways and increase overall mitochondrial health. Three specific aims will address these hypotheses. Aim 1 will assess the effects of TRT+LPWS compared to TRT+ standard neuromuscular electrical stimulation (NMES; as a control group) on the size of thigh skeletal muscle, intramuscular fat (IMF) and leg lean mass. Aim 2 will determine the association between the changes in skeletal muscle size, leg lean mass and the metabolic profile as determined by measuring BMR, serum lipids and carbohydrate profile. Aim 3 will investigate the cellular mechanisms responsible for evoking skeletal muscle hypertrophy following TRT+LPWS. This study is novel because it provides a feasible rehabilitation intervention by combining two approaches; which are likely to improve the quality of life in SCI persons with LMN denervation. If proven successful, the intervention will be easily translated into clinical practice for persons with SCI.
Dates
| Last Verified: | 05/31/2020 |
| First Submitted: | 11/12/2017 |
| Estimated Enrollment Submitted: | 11/14/2017 |
| First Posted: | 11/16/2017 |
| Last Update Submitted: | 06/22/2020 |
| Last Update Posted: | 06/24/2020 |
| Actual Study Start Date: | 06/30/2018 |
| Estimated Primary Completion Date: | 06/29/2022 |
| Estimated Study Completion Date: | 11/29/2022 |
Condition or disease
Intervention/treatment
Device: Testosterone and LPWS
Drug: Testosterone and standard NMES
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Testosterone and LPWS Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury. | Device: Testosterone and LPWS Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury. |
| Sham Comparator: Testosterone and standard NMES Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury. | Drug: Testosterone and standard NMES Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury. |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | Male |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Traumatic motor complete SCI and level of injury of T10 and below - Only participants with lower motor neuron (LMN) denervation as determined by EMG testing - Participants must also have an absence of reflexes, denervation of both knee extensor muscles - Tolerance to LPWS paradigm - Both knee extensors will also have to be unresponsive (i.e., no observed tetanic contraction or twitches) to standard electrical stimulation procedures (stimulation frequency: 30 Hz; pulse duration:450 s and amplitude of the current:200 mA) - All participants will undergo International Standards for Neurological Classification of SCI (ISNCSCI) examination for neurological level and function and only those with American Spinal Injury Classification (AIS A and B; i.e. motor deficit below the level of injury) Exclusion Criteria: - Diagnosis of neurological injury other than SCI - Pre-existing medical conditions will be excluded (cardiovascular disease, uncontrolled type II DM and those on insulin requirements) or other concurrent medical conditions judged to be contraindicated by the site physician. - Hematocrit above 50% and severe urinary tract infection or symptoms - Those with hyper-physiological testosterone level above 800 ng/dl - Those who will fail to tolerate the LPWS paradigm - Progressive condition that would be expected to result in changing neurological status - Lower extremity fracture around the knee joint (distal femur or proximal tibia) within the last 2 years from enrollment in the study - Knee BMD < 0.60 gm/cm2 - Total hip BMD T-scores < -3.5 - Untreatable severe spasticity judged to be contraindicated by the site Physician - Untreated or uncontrolled hypertension (systolic blood pressure >140 mmHg; diastolic blood pressure >90 mmHg) - Pressure ulcer of the trunk, pelvic area, or lower extremities of grade 3 or more - Psychopathology documentation in the medical record or history that may conflict with study objectives |
Outcome
Primary Outcome Measures
1. Muscle Size Change [Baseline, 6 months, and 1 year]
Secondary Outcome Measures
1. Basal Metabolic Rate [1 year]
2. Mitochondrial enzymatic activities [1 year]
